A placebo controlled, double-blind investigation of the therapeutic utility of Xolair (omalizumab) for attenuating aspirin induced bronchospasm in patients with aspirin exacerbated respiratory disease (AERD) undergoing aspirin desensitization

Trial Profile

A placebo controlled, double-blind investigation of the therapeutic utility of Xolair (omalizumab) for attenuating aspirin induced bronchospasm in patients with aspirin exacerbated respiratory disease (AERD) undergoing aspirin desensitization

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 May 2018

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Aspirin-induced asthma
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 May 2018 Primary endpoint (Spirometry (FEV1) testing to assess the efficacy of Xolair on aspirin induced bronchospasm during aspirin desensitization in patients with AERD) has been met, according to results published in the Annals of Allergy, Asthma and Immunology.
    • 16 May 2018 Results (n=16) assessing whether omalizumab administration would be associated with attenuation of aspirin provoked bronchospasm in patients with AERD undergoing aspirin desensitization, were published in the Annals of Allergy, Asthma and Immunology.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top